<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60355">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01845935</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2012/15</org_study_id>
    <nct_id>NCT01845935</nct_id>
  </id_info>
  <brief_title>Cryoablation of Venous Vascular Malformations</brief_title>
  <acronym>CRYOMAV</acronym>
  <official_title>Cryoablation of Venous Vascular Malformations Located in Soft Tissues</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To now, two alternatives for the management of venous vascular malformations are recognized,
      appropriate to the location, size and patients: sclerosis and surgery. However, sclerosis is
      effective on symptoms in 80% of cases and excision removes the malformation completely or
      partially, but it is aggressive and recurrences are common.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to propose an additional alternative option, cryoablation has been recently tested
      with promising results. Therefore, the purpose of this study is to evaluate the safety and
      efficacy of cryotherapy on venous vascular malformations.

      Fourteen patients will be included after discussion in multidisciplinary meeting. Patients
      will be follow until 6 months to evaluate the safety and the 6 months efficacy on symptoms.
      A MRI will be perform at 6 months to evaluate the size of ablated zone following RECIST
      criteria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To evaluate the safety of cryoablation by measuring the immediate complications using NCI-CTCAE toxicity scale.</measure>
    <time_frame>7 days after cryoablation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety of cryoablation by measuring the delayed complications using NCI-CTCAE toxicity scale.</measure>
    <time_frame>1 month after cryoablation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety of cryoablation by measuring the delayed complications using NCI-CTCAE toxicity scale.</measure>
    <time_frame>2 months after cryoablation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety of cryoablation by measuring the late complications using NCI-CTCAE toxicity scale.</measure>
    <time_frame>6 months after cryoablation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>All adverse events using NCI-CTCAE</measure>
    <time_frame>7 days, 1 month ,2 months + 6 months after cryoablation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response (decrease of pain and/or functional discomfort)</measure>
    <time_frame>6 months after cryoablation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging response (RECIST 1.1)</measure>
    <time_frame>6 months after cryoablation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using QLQ-C30</measure>
    <time_frame>2 months &amp; 6 months after cryoablation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain using visual analogue scale</measure>
    <time_frame>7 days, 1 month ,2 months &amp; 6 months after cryoablation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Venous Vascular Malformation</condition>
  <arm_group>
    <arm_group_label>only one treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients presenting inoperable venous vascular malformations in soft tissues with indication of cryoablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous Image-guided Cryoablation (FPRPR3508 IceRod® PLUS Needles)</intervention_name>
    <description>Treatment consists of a percutaneous cryoablation performed under anesthesia and imaging control.</description>
    <arm_group_label>only one treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18 years,

          -  Initial radiological diagnosis of venous or glomovenous vascular malformation proved
             by Doppler ultrasound and MRI,

          -  Recurrence of symptoms after initial treatment,

          -  Symptomatic deformation :pain, tangible mass,functional discomfort

          -  Recurrence after treatment by surgery or sclerosis

          -  Cryotherapy considered technically feasible after discussion in multidisciplinary
             committee,

          -  Localization at distance from the skin and major neurovascular structures,

          -  Absence of contra-indication of anaesthesia,

          -  Signed informed consent,

          -  Coverage by French social security

        Exclusion Criteria:

          -  Localization of the lesion does not allow the implementation of cryotherapy in
             adequate conditions: ablation zone too close to the major anatomic structures
             (nerve),

          -  TP &lt;50% TCA&gt; 1.5 x control, anticoagulation

          -  Platelets &lt;90000/mm3,

          -  Progressive infection

          -  Patient included in another clinical study,

          -  Unable to undergo medical tests for geographical, social or psychological,

          -  Adult under a legal guardianship or unable to consent,

          -  Pregnancy and breastfeeding.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Cornelis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bordeaux, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adelaide Doussau, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Bordeaux, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François Cornelis, MD</last_name>
    <phone>0033 5 56 79 55 99</phone>
    <email>francois.cornelis@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicolas Grenier, MD PhD</last_name>
    <phone>0033 5 56 79 55 99</phone>
    <email>Nicolas.grenier@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Bordeaux, France</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Cornelis, MD</last_name>
      <phone>0033 5 56 79 55 99</phone>
      <email>francois.cornelis@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nicolas Grenier, MD PhD</last_name>
      <phone>0033 5 56 79 55 99</phone>
      <email>Nicolas.grenier@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Cornelis F, Neuville A, Labrèze C, Kind M, Bui B, Midy D, Palussière J, Grenier N. Percutaneous cryotherapy of vascular malformation: initial experience. Cardiovasc Intervent Radiol. 2013 Jun;36(3):853-6. doi: 10.1007/s00270-012-0434-9. Epub 2012 Jun 22.</citation>
    <PMID>22722720</PMID>
  </reference>
  <reference>
    <citation>Cornelis F, Havez M, Lippa N, Al-Ammari S, Verdier D, Carteret T, Amoretti N, Gangi A, Palussiere J, Hauger O, Grenier N. Radiologically guided percutaneous cryotherapy for soft tissue tumours: A promising treatment. Diagn Interv Imaging. 2013 Apr;94(4):364-70. doi: 10.1016/j.diii.2013.02.001. Epub 2013 Mar 11. PubMed PMID: 23491212.</citation>
    <PMID>23491212</PMID>
  </reference>
  <reference>
    <citation>Barza M, Pavan PR, Doft BH, Wisniewski SR, Wilson LA, Han DP, Kelsey SF. Evaluation of microbiological diagnostic techniques in postoperative endophthalmitis in the Endophthalmitis Vitrectomy Study. Arch Ophthalmol. 1997 Sep;115(9):1142-50.</citation>
    <PMID>9298055</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 18, 2013</lastchanged_date>
  <firstreceived_date>April 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cryoablation</keyword>
  <keyword>Venous vascular malformation</keyword>
  <keyword>MRI</keyword>
  <keyword>safety</keyword>
  <keyword>pain</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Vascular Malformations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
